management of infectious complications in immunocompromised patients
DESCRIPTION
Management of Infectious Complications in Immunocompromised Patients. Abhay Dhand M.D. Director, Transplant Infectious Diseases, Westchester Medical Center, Valhalla, NY. OBJECTIVES. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/1.jpg)
Management of Infectious Complications in
Immunocompromised Patients
Abhay Dhand M.D.Director, Transplant Infectious Diseases,
Westchester Medical Center,Valhalla, NY
![Page 2: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/2.jpg)
OBJECTIVES
1. To define an immuno-compromised host.
2. To understand the role of net immune suppression in mediating the risk of infections in susceptible host.
3. To understand the epidemiology and risk factors for infections in immuno-compromised patients.
4. To learn the preventative, and diagnostic strategies for management of infections in immuno-compromised patients
![Page 3: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/3.jpg)
IMMUNOCOMPROMISED HOST
• CONGENITAL IMMUNOSUPPRESSION
• ACQUIRED IMMUNOSUPPRESSION
![Page 4: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/4.jpg)
ACQUIREDIMMUNOSUPPRESSION
• Immunosuppressive Therapy
• Microbial Infection
• Malignancy
• Disorders of biochemical homeostasis
• Autoimmune diseases
• Trauma
![Page 5: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/5.jpg)
ACQUIREDIMMUNOSUPPRESSION:
Immunosuppressive Therapy• Chemotherapy for malignancy- Neutropenia
• Treatment of autoimmune disorders
• Bone marrow transplant- ablation, graft vs. host disease
• Solid organ transplant: induction, maintenance immunosuppression, treatment of rejection
![Page 6: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/6.jpg)
ACQUIREDIMMUNOSUPPRESSION:
Microbial Infection
• HIV/AIDS
• Hepatitis B/C, co-infection with HIV
• Herpes infection, Co-infection with HIV
• Bacterial infection (super antigens)
• Parasitic infections
![Page 7: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/7.jpg)
ACQUIREDIMMUNOSUPPRESSION:
Malignancy• Lymphoma
• Leukemia
• Multiple Myeloma
• Solid tumors
![Page 8: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/8.jpg)
ACQUIREDIMMUNOSUPPRESSION:
Disorders of biochemical homeostasis
• Diabetes Mellius
• ESRD/Hemodialysis
• Cirrhosis/Hepatic insufficiency
• Malnutrition
![Page 9: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/9.jpg)
ACQUIREDIMMUNOSUPPRESSION:
Autoimmune diseases• Systemic Lupus Erythematosis
• Rheumatoid Arthritis
![Page 10: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/10.jpg)
ACQUIREDIMMUNOSUPPRESSION
• Pregnancy
• Stress
• Functional splenia
• Splenectomy
• Aging
![Page 11: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/11.jpg)
Immune Defects and Commonly Associated pathogens
Immune Defect PathogenBarrier breakdown:
Burns Pseudomonas, S. aureusTrauma Streptococcus pyogenes, S. epidermidis
Phagocytic function:Absolute decrease Enteric gram negatives, Pseudomonas,
Aspergillus spp., Candida spp.Chemotaxis S. aureus, Enteric gram negatives
Microbial killing S. aureus, Enteric gram negatives, Aspergillus spp, Burkholderia
![Page 12: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/12.jpg)
Immune Defects and Commonly Associated pathogens
Immune Defect Pathogen
Humoral Immunity:
Hypogammaglobulinemia Streptococcus pneumoniae, Hemophilus IgA deficiency Pyogenic bacteria, Giardia lambia
Asplenia Streptococcus pneumoniae, Hemophilus
Complement deficiency Pyogenic bacteria, Neisseria spp.
Cell mediated immunity: Intracellular organisms (e.g. Listeria)
Viruses (e.g. Herpes family)
Fungi ( e.g. Candida spp., Cryptococcus)
Parasites(e.g. Toxoplasma)
![Page 13: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/13.jpg)
Principles of Infection in Compromised Host: Neutropenia Nosocomial infections in neutropenic cancer
patients occur at a rate of :
46.3 episodes per 1000 neutropenic days
(48.3 episodes per 100 neutropenic patients)• The risk for infection is correlated with the
depth and duration of neutropenia • “Different” presentation
– Abscess– Pulmonary Infiltrate
![Page 14: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/14.jpg)
Principles of Infection in Compromised Host
• Etiology can be ANYTHING
• Polymicrobial Infections can be seen more commonly
• Aggressive approach to diagnosis:
CT scan, Bronchoscopy, Biopsy
• Presumptive treatment
![Page 15: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/15.jpg)
Principles of Infection in Compromised Host
• Serologic testing is generally not useful in the acute diagnostic management of immunocompromised patients.
• They often fail to generate an adequate antibody response to infection.
• Microbiologic testing should include antigen detection and/or nucleic acid detection-based assays as well as cultures.
![Page 16: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/16.jpg)
Principles of Infection in Compromised Host:
Risk of Infection
• Timing post transplant
• Type of immunosuppression
• Net state of immunosuppression
• Pathogen-pathogen interaction (role of CMV)
• Type of transplant
![Page 17: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/17.jpg)
Immunosuppressive Drugs and Mechanism of Action
![Page 18: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/18.jpg)
Antigenpresenting
cell
AACCTTIIVVAATTIIOONN
HelperT
Lymphocyte
ILIL--2 R (High affinity)2 R (High affinity)
Calcineurin inhibitorsCiclosporinTacrolimus
ActivatedT
Lymphocyte
Anti-IL2 receptor AntibodiesBasiliximabDaclizumab
Mycophenolic acidAzathioprine
Antigen /T-cellreceptor/ MHC II
IL-2IL-2
Corticosteroids
DNAsynthesis
EverolimusSirolimus
PPRROOLLIIFFEERRAATTIIOONN
TLymphocyte
TLymphocyte
![Page 19: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/19.jpg)
Morbidity and Mortality in Organ Transplant Recipients - Major Causes
• Allograft Loss
– life-long requirement - exogenous immunosuppression
– major threat - chronic rejection - immunologically mediated, but poorly responsive to immunosuppression
• Life threatening infection– ~ 67% transplant recipients develop infection in
first year post - transplant; – ~ 25% eventually die of infection
• Malignancy
• Cardiovascular complications
![Page 20: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/20.jpg)
Infections in Solid Organ Transplantation patients
![Page 21: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/21.jpg)
What are the Risk Factors for Infection in Organ Transplantation?
• Exposure to infectious pathogens (endogenous and exogenous)
• “Net State of Immunosuppression”
![Page 22: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/22.jpg)
IMMUNOSUPPRESSION
LESS
- MORE REJECTION- LESS INFECTION/ MALIGNANCY
- LESS REJECTION- MORE INFECTION/ MALIGNANCY
MORE
Relationship between Infection and Immunosuppression
![Page 23: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/23.jpg)
INFECTIONS IN RECIPIENT
INFECTIONS IN DONOR
TECHNICAL COMPLICATIONS
RELATED TO TRANSPLANTPROCEDURE
PRE-TRANSPLANT
IMMUNOSUPPRESSIO
N
INFECTIOUS EXPOSURES
POST-TRANSPLANT
RISK OF INFECTION
![Page 24: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/24.jpg)
Complications of Transplantation that Predispose to Infection
• Contamination of the allograft during harvesting, transport or implantation
• Anastomotic leak• Hematoma, infarcted tissue• Presence of vascular access devices• Presence and mismanagement of endotracheal tubes• Presence of urinary, biliary or other drainage catheters
![Page 25: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/25.jpg)
Net State of Immunosuppression
• Complex, poorly explained, combination of– exogenous immunosuppression – neutropenia– metabolic abnormalities (protein calorie
malnutrition, uremia, etc.)– infection with immunomodulating viruses (Herpes
group viruses particularly CMV, EBV, hepatitis viruses, HIV)
![Page 26: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/26.jpg)
Potential Exposures - Post-transplant
• Nosocomial organisms (bacteria, fungi)
• Opportunistic organisms from environment (e.g. cryptococcus, aspergillus)
• Respiratory viruses and bacteria in the community
• Organisms in contaminated food and water (e.g. salmonella, listeria)
![Page 27: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/27.jpg)
Immunosuppressive Therapy - what you need to know
• What was used for induction immunosuppression – induction with polyclonal, MAB preparations – increased
risk for opportunistic infection
• What was used as maintenance immunosuppression– How quickly did the patient get to maintenance
• What and when was anti-rejection therapy used– The trouble makers
![Page 28: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/28.jpg)
Induction Immunosuppression
• Anti-T/B cell preparations– Used in patients with highest risk of rejection,
multiple prior transplants
• Allows delay in use of nephrotoxic immunosuppression (CyA, Tacrolimus)
• Result – Watch out - increase in infection
![Page 29: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/29.jpg)
Maintenance Immunosuppression
• Renal– CyA/FK + mycophenolate + prednisone– problem = drug toxicities …organ dysfunction...infection
• Other solid organ transplants– FK + mycophenolate + prednisone– problem = drug toxicities …organ dysfunction...infection
![Page 30: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/30.jpg)
Anti-rejection therapy
• Aggressive immunosuppression– higher doses of usual immunosuppression (e.g.
steroid pulses, etc.)– Polyclonal AB and MABs
• Result – significant increase in infection – need for
additional prophylaxis
![Page 31: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/31.jpg)
When do Infections Occur in Transplant Recipients?
0 1 2 3 4 5 6 7
BACTERIAL
VIRAL
FUNGAL
Wound, pneumonia, line sepsis
Bacteremia, urosepsis, biliary, etc
Listeria
CMV
EBV, Hepatitis C
Aspergillus, PCP
Cryptococcus
HSV
Months post-transplant
![Page 32: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/32.jpg)
First Month, Post-transplantation
• Infection that was present pre-transplant (pneumonia, bacteremia/line sepsis, etc.)
• Infection from contaminated allograft
• Typical bacterial, Candidal infections seen in post-operative patients
• NOTE - NO OPPORTUNISTIC INFECTIONS - UNLESS UNUSUAL HAZARD PRESENT
![Page 33: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/33.jpg)
Month 2-6, Post-transplantation
• Immunomodulating viruses - particularly CMV, EBV, hepatitis B, C
• Opportunistic pathogens - Listeria, PCP, Aspergillus
• Residual bacterial, fungal infections from transplant complications
• NOTE - MOSTLY OPPORTUNISTIC INFECTIONS
![Page 34: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/34.jpg)
> 6 Months, Post-transplantation
• 80% patients - good allograft function, minimal immunosuppression - usual community acquired ID
• 10% patients - chronic viral infections ….. Progress to end organ failure, sepsis, etc.
• 10% patients - continuing acute, chronic rejection, more immunosuppression, continuing risk of opportunistic infection
![Page 35: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/35.jpg)
What Type of Infections Occur in Transplant Recipients?
• Sources of infection – limitless, but usually follow a timetable
– bacterial > viral > fungal
• Presentation of infection – infection difficult to recognize - signs blunted because of
impaired immune response
– unusual presentations
– chronic or relapsing infection
• Therapy challenging– prolonged courses
– adverse interactions with immunosuppressive agents
![Page 36: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/36.jpg)
CMV and Solid Organ Transplantation• CMV is still among the most important
infectious complications after transplant
• In the absence of prophylaxis, CMV reactivation can occur in over 75% of solid organ transplant recipients depending on other risk factors
• Once CMV infection is established, then its replication is highly dynamic with rapid increases in viral load
![Page 37: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/37.jpg)
Risk of Symptomatic CMV Disease
• Serologic status of donor and recipient
• Type of organ transplanted
• Type of immunosuppression
![Page 38: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/38.jpg)
CMV Infection: Risk Categories in Solid Organ Transplant Recipients
Risk CategoryDonor (D) or Recipient (R)
Seropositivity (+/-)
High D+/R-
Intermediate* D+/R+, D-/R+
Low D-/R-* D+/R+ generally at higher risk than D-/R+
![Page 39: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/39.jpg)
0
10
20
30
40
50
Kidney Heart Liver Heart-Lung orLung
Risk of Developing CMV Disease
Percent with CMV Disease
CMV Disease in SOT
![Page 40: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/40.jpg)
Indirect Effects of CMV Infection
Altered host immune response
• Graft rejection; graft dysfunction
• Opportunistic infections: Bacterial fungal superinfection
• Decreased graft and patient survival
• Herpesvirus interactions: EBV/PTLD
Indirect Effects
![Page 41: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/41.jpg)
Strategies for Prevention of Infection in Transplant Patients
• Pre-transplant
• Peri-transplant
• Post-transplant
![Page 42: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/42.jpg)
Strategies for Prevention of Infection in Transplant Patients: PRE-TRANSPLANT
• Evaluate for active infection
• Evaluate for colonization with MDROs
• Evaluate for latent infections
• Vaccination
![Page 43: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/43.jpg)
Strategies for Prevention of Infection in Transplant Patients: PERI-TRANSPLANT
Antibiotic prophylaxis:
• Goal: decrease the risk of surgical site infection, donor derived infection, disseminated infection, active treatment of latent/occult infection
• Type of transplant, h/o colonization, active localized infection, infection/colonization in the donor, antibiotic allergies
![Page 44: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/44.jpg)
Strategies for Prevention of Infection in Transplant Patients: POST-TRANSPLANT
Prophylaxis:Antibiotics: bactrim, ciprofloxacin
Anti-viral: herpes viruses (CMV): valganciclovir
Anti-fungal: candida, aspergillus, endemic funguses
![Page 45: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/45.jpg)
Candida Prophylaxis
• Liver transplant:
Atleast 2 risk factors: re-transplantation, Cr>2mg/dl, choledochojejunostomy, prolonged intra-operative time,
use of >40 U of blood products, fungal colonization 2 days before and 3 days after transplant.
• Heart/Kidney: not required
• Pancreas, Small bowel
![Page 46: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/46.jpg)
Aspergillosis Prophylaxis
• Heart transplant recipients:
Isolation of aspergillus in airway cultures
Repeat thoracic surgery
CMV disease
Posttransplant renal replacement therapy• Liver transplant recipients:
Retransplantation, renal replacement therapy
Repeat intra-abdominal or thoracic surgery
4 weeks post transplant
Transplant for fulminant hepatic failure
![Page 47: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/47.jpg)
Prevention of Nosocomial Infections
![Page 48: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/48.jpg)
“Ventilator Bundle”
Head of bed elevation > 30 degrees*
Daily “sedation vacation” and assessment of readiness to extubate*
Oral care (chlorhexidine)
Peptic ulcer disease prophylaxis*
Deep vein thrombosis prophylaxis*
*Institute for Healthcare Improvement
Reduction in VAP from 6.6 to 2.7 (59%) per 1000 ventilator-days with > 95%
compliance
![Page 49: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/49.jpg)
Hospital-Acquired UTI
40% of healthcare-associated infections80% due to indwelling urethral catheter
Potential Strategies Insertion/care
Catheter reminders/automatic stop ordersBladder US scanners
Condom cathetersAntimicrobial catheters
Clin Infect Dis 2008;46:243-50
![Page 50: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/50.jpg)
- Multimodal intervention- Bundle approach- The “last mile” may require the use of
some technical device (chlorhexidine patch, coated catheters, antibiotic impregnated device, lock solutions…)
Zero Central Line Associated Bloodstream Infections:
…how to get there…
![Page 51: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/51.jpg)
Colonization with Antibiotic Resistant Organisms:
Risk of Nosocomial Infections
![Page 52: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/52.jpg)
![Page 53: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/53.jpg)
![Page 54: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/54.jpg)
Decolonization and its Role in Prevention of Nosocomial Infections
![Page 55: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/55.jpg)
Arch Intern Med 2006; 166:306-12
Chlorhexidine Body Wash in the ICU
Arch Intern med 2007;167:2073-79
Decreased Acquisition of VREBefore and after, compared with soap and water
Decreased Bloodstream InfectionsCross-over, compared with soap and water
6.4 vs. 16.8 BSI per 1000 catheter-days
![Page 56: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/56.jpg)
Selective Colonization: CDI
![Page 57: Management of Infectious Complications in Immunocompromised Patients](https://reader036.vdocument.in/reader036/viewer/2022062518/5681446b550346895db0ff2d/html5/thumbnails/57.jpg)
Selective Colonization: CDI
• Restore microbiota: fecal bacteriotherapy
• Nontoxigenic Clostridium Difficle